Identification and characterization of a cross-neutralization epitope of Enterovirus 71

Chia Chyi Liu, Ai Hsiang Chou, Shu Pei Lien, Hsiao Yu Lin, Shih Jen Liu, Jui Yuan Chang, Meng Shin Guo, Yen Hung Chow, Wun Syue Yang, Kate Hsuen Wen Chang, Charles Sia, Pele Chong

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136-150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1-43 was identified within residues 211-220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1. nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.

Original languageEnglish
Pages (from-to)4362-4372
Number of pages11
JournalVaccine
Volume29
Issue number26
DOIs
Publication statusPublished - Jun 10 2011
Externally publishedYes

Fingerprint

Enterovirus
neutralization
epitopes
Epitopes
Vaccines
vaccines
Genotype
Formaldehyde
formalin
Immune Sera
antiserum
genotype
synthetic peptides
Viruses
Neutralizing Antibodies
Virion
Peptides
virion
neutralizing antibodies
viruses

Keywords

  • Cross-genotype neutralizing antibody
  • EV71 vaccine
  • Hand-foot-and-mouth disease (HFMD)
  • Inactivated whole virion vaccine
  • Potency assay development

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Liu, C. C., Chou, A. H., Lien, S. P., Lin, H. Y., Liu, S. J., Chang, J. Y., ... Chong, P. (2011). Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine, 29(26), 4362-4372. https://doi.org/10.1016/j.vaccine.2011.04.010

Identification and characterization of a cross-neutralization epitope of Enterovirus 71. / Liu, Chia Chyi; Chou, Ai Hsiang; Lien, Shu Pei; Lin, Hsiao Yu; Liu, Shih Jen; Chang, Jui Yuan; Guo, Meng Shin; Chow, Yen Hung; Yang, Wun Syue; Chang, Kate Hsuen Wen; Sia, Charles; Chong, Pele.

In: Vaccine, Vol. 29, No. 26, 10.06.2011, p. 4362-4372.

Research output: Contribution to journalArticle

Liu, CC, Chou, AH, Lien, SP, Lin, HY, Liu, SJ, Chang, JY, Guo, MS, Chow, YH, Yang, WS, Chang, KHW, Sia, C & Chong, P 2011, 'Identification and characterization of a cross-neutralization epitope of Enterovirus 71', Vaccine, vol. 29, no. 26, pp. 4362-4372. https://doi.org/10.1016/j.vaccine.2011.04.010
Liu, Chia Chyi ; Chou, Ai Hsiang ; Lien, Shu Pei ; Lin, Hsiao Yu ; Liu, Shih Jen ; Chang, Jui Yuan ; Guo, Meng Shin ; Chow, Yen Hung ; Yang, Wun Syue ; Chang, Kate Hsuen Wen ; Sia, Charles ; Chong, Pele. / Identification and characterization of a cross-neutralization epitope of Enterovirus 71. In: Vaccine. 2011 ; Vol. 29, No. 26. pp. 4362-4372.
@article{3bfbcc9d56cc45b087b09cf880527da1,
title = "Identification and characterization of a cross-neutralization epitope of Enterovirus 71",
abstract = "Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136-150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1-43 was identified within residues 211-220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1. nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.",
keywords = "Cross-genotype neutralizing antibody, EV71 vaccine, Hand-foot-and-mouth disease (HFMD), Inactivated whole virion vaccine, Potency assay development",
author = "Liu, {Chia Chyi} and Chou, {Ai Hsiang} and Lien, {Shu Pei} and Lin, {Hsiao Yu} and Liu, {Shih Jen} and Chang, {Jui Yuan} and Guo, {Meng Shin} and Chow, {Yen Hung} and Yang, {Wun Syue} and Chang, {Kate Hsuen Wen} and Charles Sia and Pele Chong",
year = "2011",
month = "6",
day = "10",
doi = "10.1016/j.vaccine.2011.04.010",
language = "English",
volume = "29",
pages = "4362--4372",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",

}

TY - JOUR

T1 - Identification and characterization of a cross-neutralization epitope of Enterovirus 71

AU - Liu, Chia Chyi

AU - Chou, Ai Hsiang

AU - Lien, Shu Pei

AU - Lin, Hsiao Yu

AU - Liu, Shih Jen

AU - Chang, Jui Yuan

AU - Guo, Meng Shin

AU - Chow, Yen Hung

AU - Yang, Wun Syue

AU - Chang, Kate Hsuen Wen

AU - Sia, Charles

AU - Chong, Pele

PY - 2011/6/10

Y1 - 2011/6/10

N2 - Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136-150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1-43 was identified within residues 211-220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1. nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.

AB - Enterovirus 71 (EV71) infections in children manifest as exanthema and are most commonly known as hand-foot-and-mouth disease (HFMD). Because it can cause severe neurological complications like poliomyelitis, EV71 has now emerged as an important neurotropic virus in Asia. EV71 virus has been shown to consist of 3 (A, B and C) genotypes and many subgenotypes. Although EV71 vaccine development has recently yielded promising preclinical results, yet the correlation between the content of antigen(s) in vaccine candidates and the level of protective antibody responses is not established. The neutralization epitope(s) of EV71 antigens could be used as the surrogate biomarker of vaccine potency. Using peptide ELISA, antisera generated from animals immunized with formalin-inactivated EV71 virion vaccine formulated in alum, EV71-specific neutralizing monoclonal antibody (nMAb) and a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71, we screened for immunodominant linear neutralization epitope(s). Synthetic peptide VP2-28, corresponding to residues 136-150 of VP2, was found to bind to and inhibit the binding to EV71 of nMAb MAB979 that was found to have cross-neutralizing activity against different genotypes of EV71 virus. In addition, VP2-28 was found to be recognized only by neutralizing antisera generated from rabbits immunized with the formalin-inactivated whole EV71 virion vaccine but not by antisera from immunized mice and rats. During the epitope mapping, a murine EV71 genotype- and strain-specific linear neutralization epitope VP1-43 was identified within residues 211-220 of VP1. Furthermore, based on sequence alignment and structure prediction analysis using poliovirus as the template for molecular modeling, the VP1-43 and VP2-28 epitopes were shown to run in parallel within 0.1. nm and form a rim of the canyon at the junction site of VP1 and VP2 in the viral capsid. In mouse, rat and rabbit immunogenicity studies, a dose-dependent relationship between the number of VP2-28 epitope units measured by a quantitative assay in vaccine preparations and the magnitude of neutralizing titers was demonstrated. VP2-28 has amino acid sequences that are highly conserved among EV71 genotypes, is not affected by formalin-treatment and long-term storage. Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines.

KW - Cross-genotype neutralizing antibody

KW - EV71 vaccine

KW - Hand-foot-and-mouth disease (HFMD)

KW - Inactivated whole virion vaccine

KW - Potency assay development

UR - http://www.scopus.com/inward/record.url?scp=79957836497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957836497&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.04.010

DO - 10.1016/j.vaccine.2011.04.010

M3 - Article

VL - 29

SP - 4362

EP - 4372

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -